<?xml version='1.0' encoding='utf-8'?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2011//EN" "http://www.ncbi.nlm.nih.gov/entrez/query/DTD/pubmed_110101.dtd">
<pubmedarticleset>
 <pubmedarticle>
  <medlinecitation owner="NLM" status="MEDLINE">
   <pmid version="1">
    10908470
   </pmid>
   <datecreated>
    <year>
     2001
    </year>
    <month>
     01
    </month>
    <day>
     03
    </day>
   </datecreated>
   <datecompleted>
    <year>
     2001
    </year>
    <month>
     07
    </month>
    <day>
     05
    </day>
   </datecompleted>
   <daterevised>
    <year>
     2007
    </year>
    <month>
     10
    </month>
    <day>
     18
    </day>
   </daterevised>
   <article pubmodel="Print">
    <journal>
     <issn issntype="Electronic">
      1469-493X
     </issn>
     <journalissue citedmedium="Internet">
      <issue>
       3
      </issue>
      <pubdate>
       <year>
        2000
       </year>
      </pubdate>
     </journalissue>
     <title>
      Cochrane database of systematic reviews (Online)
     </title>
     <isoabbreviation>
      Cochrane Database Syst Rev
     </isoabbreviation>
    </journal>
    <articletitle>
     Interventions for treating scabies.
    </articletitle>
    <pagination>
     <medlinepgn>
      CD000320
     </medlinepgn>
    </pagination>
    <abstract>
     <abstracttext label="BACKGROUND" nlmcategory="BACKGROUND">
      Scabies is a common public health problem with an estimated global prevalence of 300 million. Infestation can cause considerable discomfort and intense itching. Severe adverse effects have been reported for some drugs used to treat scabies.
     </abstracttext>
     <abstracttext label="OBJECTIVES" nlmcategory="OBJECTIVE">
      The objective of this review is to assess the effects and toxicity of topical and systemic drug treatment for scabies.
     </abstracttext>
     <abstracttext label="SEARCH STRATEGY" nlmcategory="METHODS">
      We searched the Cochrane Infectious Diseases Group trials register, the Cochrane Controlled Trials Register, MEDLINE, EMBASE, military records, traditional medicine databases. We also contacted international specialist centres and drug manufacturers.
     </abstracttext>
     <abstracttext label="SELECTION CRITERIA" nlmcategory="METHODS">
      Randomised controlled trials of any drug treatment for scabies. Tolerability and toxicity were sought in any study of humans taking any drug treatments for scabies.
     </abstracttext>
     <abstracttext label="DATA COLLECTION AND ANALYSIS" nlmcategory="METHODS">
      Two reviewers assessed trial quality and extracted data.
     </abstracttext>
     <abstracttext label="MAIN RESULTS" nlmcategory="RESULTS">
      Thirteen trials were included (nine compared drug treatments, two compared treatment regimens, one compared the drug vehicle, and one was a community intervention). In one small trial, ivermectin was associated with a significant higher clinical cure rate at seven days when compared with placebo. Permethrin appeared to be more effective than crotamiton for clinical and parasitic cure rates. Permethrin appeared to be better than lindane for clinical cure rates in two small trials, but had no advantage in the largest trial (test for heterogeneity P &lt; 0.001). Permethrin also appeared more effective in reducing itch persistence than lindane. There appeared to be no difference in clinical cure rates between crotamiton and lindane or benzyl benzoate and sulphur. Two trials assessed: the effectiveness of oral versus topical treatment (ivermectin versus benzyl benzoate and ivermectin ); single trial assessed treatment vehicle (pork fat versus cold cream); and mass community treatment (ivermectin), but all were too small to demonstrate an effect. No randomised trials of malathion were identified. Serious adverse drug reactions (including death and convulsions), most notably to lindane, permethrin and ivermectin, have been reported elsewhere.
     </abstracttext>
     <abstracttext label="REVIEWER'S CONCLUSIONS" nlmcategory="CONCLUSIONS">
      The evidence that permethrin is more effective than lindane is inconsistent. Lindane, permethrin, and ivermectin appear to be associated with rare but serious drug reactions although this is not derived from trial data. More research is needed on the safety and effectiveness of ivermectin and malathion compared to permethrin, on community management, and on different regimens and vehicles for topical treatment.
     </abstracttext>
    </abstract>
    <affiliation>
     Country Support Team for Central and South Asia, UNFPA, PO Box 5940, Kathmandu, Nepal. gwalker@unfpa.wlink.com.np
    </affiliation>
    <authorlist completeyn="Y">
     <author validyn="Y">
      <lastname>
       Walker
      </lastname>
      <forename>
       G J
      </forename>
      <initials>
       GJ
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Johnstone
      </lastname>
      <forename>
       P W
      </forename>
      <initials>
       PW
      </initials>
     </author>
    </authorlist>
    <language>
     eng
    </language>
    <publicationtypelist>
     <publicationtype>
      Journal Article
     </publicationtype>
     <publicationtype>
      Review
     </publicationtype>
    </publicationtypelist>
   </article>
   <medlinejournalinfo>
    <country>
     ENGLAND
    </country>
    <medlineta>
     Cochrane Database Syst Rev
    </medlineta>
    <nlmuniqueid>
     100909747
    </nlmuniqueid>
    <issnlinking>
     1361-6137
    </issnlinking>
   </medlinejournalinfo>
   <chemicallist>
    <chemical>
     <registrynumber>
      0
     </registrynumber>
     <nameofsubstance>
      Insecticides
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      0
     </registrynumber>
     <nameofsubstance>
      Pyrethrins
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      0
     </registrynumber>
     <nameofsubstance>
      Toluidines
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      58-89-9
     </registrynumber>
     <nameofsubstance>
      Lindane
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      70288-86-7
     </registrynumber>
     <nameofsubstance>
      Ivermectin
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      7704-34-9
     </registrynumber>
     <nameofsubstance>
      Sulfur
     </nameofsubstance>
    </chemical>
   </chemicallist>
   <citationsubset>
    IM
   </citationsubset>
   <commentscorrectionslist>
    <commentscorrections reftype="UpdateIn">
     <refsource>
      Cochrane Database Syst Rev. 2007;(3):CD000320
     </refsource>
     <pmid version="1">
      17636630
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="UpdateOf">
     <refsource>
      Cochrane Database Syst Rev. 2000;(2):CD000320
     </refsource>
     <pmid version="1">
      10796527
     </pmid>
    </commentscorrections>
   </commentscorrectionslist>
   <meshheadinglist>
    <meshheading>
     <descriptorname majortopicyn="N">
      Humans
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Insecticides
     </descriptorname>
     <qualifiername majortopicyn="N">
      therapeutic use
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Ivermectin
     </descriptorname>
     <qualifiername majortopicyn="N">
      therapeutic use
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Lindane
     </descriptorname>
     <qualifiername majortopicyn="N">
      therapeutic use
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Pyrethrins
     </descriptorname>
     <qualifiername majortopicyn="N">
      therapeutic use
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Scabies
     </descriptorname>
     <qualifiername majortopicyn="N">
      drug therapy
     </qualifiername>
     <qualifiername majortopicyn="Y">
      therapy
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Sulfur
     </descriptorname>
     <qualifiername majortopicyn="N">
      therapeutic use
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Toluidines
     </descriptorname>
     <qualifiername majortopicyn="N">
      therapeutic use
     </qualifiername>
    </meshheading>
   </meshheadinglist>
   <numberofreferences>
    101
   </numberofreferences>
  </medlinecitation>
  <pubmeddata>
   <history>
    <pubmedpubdate pubstatus="pubmed">
     <year>
      2000
     </year>
     <month>
      7
     </month>
     <day>
      25
     </day>
     <hour>
      11
     </hour>
     <minute>
      0
     </minute>
    </pubmedpubdate>
    <pubmedpubdate pubstatus="medline">
     <year>
      2001
     </year>
     <month>
      7
     </month>
     <day>
      6
     </day>
     <hour>
      10
     </hour>
     <minute>
      1
     </minute>
    </pubmedpubdate>
    <pubmedpubdate pubstatus="entrez">
     <year>
      2000
     </year>
     <month>
      7
     </month>
     <day>
      25
     </day>
     <hour>
      11
     </hour>
     <minute>
      0
     </minute>
    </pubmedpubdate>
   </history>
   <publicationstatus>
    ppublish
   </publicationstatus>
   <articleidlist>
    <articleid idtype="pubmed">
     10908470
    </articleid>
    <articleid idtype="pii">
     CD000320
    </articleid>
    <articleid idtype="doi">
     10.1002/14651858.CD000320
    </articleid>
   </articleidlist>
  </pubmeddata>
 </pubmedarticle>
</pubmedarticleset>

